Table 1: Selection, Design & Construction
of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction
of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction
of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction
of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction
of Newcastle
Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction
of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials
of T - Vec Table 8: Clinical Trials
of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials
of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development
Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design
of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies
of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development
Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources
of Technology Table 26:
Second Generation Oncology Virus Companies and their Sources
of Technology Table 27: Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
A major challenge that will be addressed in the
second phase of LINCS is to optimize the combinations
of cell types, perturbations and measurements
of cellular responses to address a wider range
of basic biological and
disease - related problems than was possible in the program's initial pilot stage, said Alan Michelson, M.D., Ph.D., senior investigator, Laboratory
of Developmental Systems Biology, NHLBI, and co-chair
of the NIH LINCS Project Implementation Team.
October 1, 2015 University
of Chicago researchers awarded $ 3.5 million as part
of national consortium to transform diagnosis and treatment
of psychotic disorders The National Institute
of Mental Health (NIMH) has awarded researchers from the University
of Chicago $ 3.5 million as part
of the
second phase of the Bipolar - Schizophrenia Network on Intermediate Phenotypes (B - SNIP2)-- a multi-university consortium that aims to establish a new system
of diagnosis for psychotic
diseases based on biomarkers, and guide the development
of novel therapies.